Opportunity Information: Apply for PAR 15 331
Apply for PAR 15 331
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management (U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396 Cancer Biology Research.
- This funding opportunity was created on Aug 18, 2015 and posted on Aug 18, 2015.
- Applicants must submit their applications by Jun 14, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $600,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) County governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public and State controlled institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Advanced Development of Informatics Technologies for Cancer Research and Management (U24) opportunity (Funding Opportunity Number PAR 15-331) is a National Institutes of Health cooperative agreement focused on moving promising cancer informatics tools from a proven pilot stage into a stronger, more impactful, and more broadly usable technology. It sits within the National Cancer Institute (NCI) Informatics Technology for Cancer Research (ITCR) Initiative, which is designed to support informatics technologies across the full development lifecycle, especially when they address real, high-priority needs in cancer research. The overall aim is to improve how cancer-related data and knowledge are acquired, managed, analyzed, and shared, spanning the full cancer research continuum, including cancer biology, diagnosis and treatment, prevention, control and epidemiology, and cancer health disparities.
This FOA specifically targets "emerging informatics technology" that is beyond the earliest prototyping and pilot testing phase. In practical terms, the project being proposed should already exist in a credible form and have shown enough promise to justify additional investment, but it should not yet be widely adopted within the cancer research community. The intent is not to fund brand-new ideas from scratch or simply keep an existing widely used resource running, but to fund advanced development and enhancement that will make the technology more robust, more feature-complete, more scalable, easier to use, and more likely to be adopted by the broader field. Technologies supported under this mechanism are expected to have clear potential for significant impact across multiple users, projects, or institutions, rather than being narrowly tailored to one local environment.
A key expectation of applicants is to present a development plan with a clear, evidence-based rationale for why the technology is needed and how it will benefit cancer research. That means proposals should make the case that there is a real gap or inefficiency in current workflows or capabilities, and that the proposed enhancements will materially improve research or data practices. Another central requirement is that the project actively involves users and collaborators throughout the development process. Rather than building in isolation, teams are expected to include practical mechanisms for gathering ongoing feedback, such as user testing, engagement with scientific collaborators, advisory groups, community input, iterative releases, or other structured approaches that keep development aligned with real-world needs.
The award uses the cooperative agreement (U24) mechanism, which generally implies substantial programmatic involvement from NIH compared to a standard research grant. In many cooperative agreements, NIH staff may participate in steering, coordination, or milestone-focused oversight to ensure the technology development stays aligned with program goals and has a strong chance of producing a broadly useful deliverable. The FOA is categorized under health and education-related funding activity, and it is tied to CFDA number 93.396 (Cancer Biology Research). There is no cost sharing or matching requirement listed. The award ceiling is noted as $600,000, indicating the maximum funding level anticipated per award under this announcement.
Eligibility is broad and includes many types of U.S.-based organizations. Eligible applicants include public and private institutions of higher education, public/state-controlled universities, nonprofits with or without 501(c)(3) status, small businesses, for-profit organizations (other than small businesses), and multiple levels of government such as state, county, city/township, special district governments, and public or Indian housing authorities. The FOA also explicitly includes a range of mission-driven and community-serving institutions and entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), faith-based or community-based organizations, regional organizations, and certain eligible federal agencies. Foreign institutions and non-U.S. organizational components are not eligible to apply directly, though foreign components (as defined by the NIH Grants Policy Statement) are allowed, meaning a U.S. applicant organization may include some foreign collaboration elements if they meet NIH policy requirements.
In terms of timing, the FOA was posted and created on August 18, 2015, and had an original and current closing date of June 14, 2018, with an archive date of July 15, 2018. The administering agency is the National Institutes of Health, with the program housed in NCI through the ITCR Initiative. The full announcement was available via the NIH grants guide page listed in the additional information link (http://grants.nih.gov/grants/guide/pa-files/PAR-15-331.html). For access or technical issues, NIH directed applicants to contact the NIH Office of Extramural Research (OER) webmaster email addresses provided in the notice.
Overall, this opportunity was designed for teams that already have a functioning cancer informatics technology with demonstrated promise, but that still needs substantial engineering and product-level advancement to become reliable, scalable, user-friendly, and broadly adopted across the cancer research community. It emphasizes impact, real user need, iterative improvement based on feedback, and the practical translation of informatics innovation into tools that improve cancer research data and knowledge workflows.
FAQs: Advanced Development of Informatics Technologies for Cancer Research and Management (U24) - PAR-15-331
What is PAR-15-331 (U24) in plain terms?
PAR-15-331 is a National Institutes of Health (NIH) cooperative agreement funding opportunity from the National Cancer Institute (NCI) that supports advanced development of promising cancer informatics technologies. It is meant to take tools that have already proven themselves in a pilot stage and strengthen them into more robust, scalable, user-friendly technologies that can be adopted broadly by the cancer research community.
Which NIH program is this opportunity part of?
This opportunity sits within NCI's Informatics Technology for Cancer Research (ITCR) Initiative, which supports cancer informatics technologies across the full development lifecycle when they address real, high-priority needs in cancer research.
What is the main goal of this funding opportunity?
The overall aim is to improve how cancer-related data and knowledge are acquired, managed, analyzed, and shared. The FOA emphasizes moving a credible, promising tool beyond pilot-stage success into a stronger, more impactful, and more broadly usable technology.
What parts of cancer research does this opportunity cover?
The scope spans the full cancer research continuum, including cancer biology, diagnosis and treatment, prevention, control and epidemiology, and cancer health disparities.
What stage of technology is this FOA targeting?
This FOA targets "emerging informatics technology" that is beyond earliest prototyping and pilot testing. The proposed technology should already exist in a credible form and have demonstrated enough promise to justify additional investment, but it should not yet be widely adopted by the broader cancer research community.
Does this funding support brand-new ideas built from scratch?
No. The intent is not to fund brand-new ideas starting from zero. The focus is advanced development and enhancement of an already functioning technology that has demonstrated promise.
Is this funding meant to keep an already widely used resource running?
No. The FOA is not intended to simply maintain or keep operating an already widely adopted resource. It is intended for substantial enhancement that improves robustness, usability, scalability, and likelihood of broader adoption.
What kinds of improvements is the program looking for?
The FOA emphasizes work that makes a technology more robust, more feature-complete, more scalable, easier to use, and more likely to be adopted widely. In other words, it supports engineering and product-level advancement rather than just early proof-of-concept work.
How broad does the expected impact need to be?
Technologies supported under this mechanism are expected to have clear potential for significant impact across multiple users, projects, or institutions. The FOA emphasizes broad usability rather than tools designed only for a single local environment.
What does the FOA require in terms of need and justification?
Applicants are expected to present a development plan with a clear, evidence-based rationale for why the technology is needed and how it will benefit cancer research. Proposals should explain the gap or inefficiency in current workflows and how the proposed enhancements will materially improve research or data practices.
How important is user involvement and feedback in this program?
User involvement is a central requirement. The FOA expects teams to actively involve users and collaborators throughout development using practical mechanisms such as user testing, engagement with scientific collaborators, advisory groups, community input, iterative releases, or other structured approaches that keep development aligned with real-world needs.
What does it mean that this is a U24 cooperative agreement?
The award uses the NIH cooperative agreement (U24) mechanism, which generally implies substantial programmatic involvement from NIH compared to a standard research grant. NIH staff may participate in steering, coordination, or milestone-focused oversight to help keep the technology development aligned with program goals and positioned to deliver a broadly useful outcome.
Which NIH institute administers this opportunity?
The administering agency is the National Institutes of Health (NIH), and the program is housed in the National Cancer Institute (NCI) through the ITCR Initiative.
What is the CFDA number associated with this opportunity?
The FOA is tied to CFDA number 93.396 (Cancer Biology Research).
Is there a cost sharing or matching requirement?
No cost sharing or matching requirement is listed in the information provided.
What is the maximum funding level mentioned for this FOA?
The award ceiling is noted as $600,000, indicating the maximum funding level anticipated per award under this announcement.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations, including public and private institutions of higher education, public/state-controlled universities, nonprofits with or without 501(c)(3) status, small businesses, for-profit organizations (other than small businesses), and various government entities (state, county, city/township, special district governments, and public or Indian housing authorities).
Are community-serving and mission-driven institutions included in eligibility?
Yes. The FOA explicitly includes institutions and entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), faith-based or community-based organizations, regional organizations, and certain eligible federal agencies.
Can foreign institutions apply directly?
No. Foreign institutions and non-U.S. organizational components are not eligible to apply directly based on the information provided.
Are foreign components allowed at all?
Yes. Foreign components (as defined by the NIH Grants Policy Statement) are allowed, meaning a U.S. applicant organization may include foreign collaboration elements if they meet NIH policy requirements.
When was this FOA posted, and when did it close?
The FOA was posted/created on August 18, 2015. The original and current closing date was June 14, 2018, and the archive date was July 15, 2018.
Where could applicants find the full FOA announcement?
The full announcement was available via the NIH Grants Guide page at: http://grants.nih.gov/grants/guide/pa-files/PAR-15-331.html
Who should be contacted for access or technical issues with the announcement page?
For access or technical issues, NIH directed applicants to contact the NIH Office of Extramural Research (OER) webmaster email addresses provided in the notice (as referenced in the opportunity information).
What type of project is a strong fit for this opportunity overall?
A strong fit is a team with a functioning cancer informatics technology that has demonstrated promise in a pilot setting, but still needs substantial advanced development to become reliable, scalable, user-friendly, and broadly adopted. The FOA emphasizes impact, clear user need, iterative improvement based on feedback, and practical translation into tools that improve cancer research data and knowledge workflows.
Browse more opportunities from the same category: Education Health
Next opportunity: Sustained Support for Informatics Resources for Cancer Research and Management (U24)
Previous opportunity: Early Stage Development of Informatics Technologies for Cancer Research and Management (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 15 331
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 15 331) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sustained Support for Informatics Resources for Cancer Research and Management (U24) Apply for PAR 15 333 Funding Number: PAR 15 333 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) Apply for PAR 15 334 Funding Number: PAR 15 334 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Multi site Palliative Care Research in Diverse Populations Utilizing the Palliative Care Research Cooperative (PCRC) Group (R21) Apply for PAR 15 337 Funding Number: PAR 15 337 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| NIDA Translational Avant Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 16 008 Funding Number: RFA DA 16 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Apply for PAR 15 340 Funding Number: PAR 15 340 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Centers for Cancer Systems Biology Consortium(U54) Apply for RFA CA 15 014 Funding Number: RFA CA 15 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,500,000 |
| Coordinating Center for Cancer Systems Biology Consortium (U24) Apply for RFA CA 15 015 Funding Number: RFA CA 15 015 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Behavioral Pharmacology and Genetics Translating and Targeting Individual Differences (R03) Apply for RFA DA 09 016 Funding Number: RFA DA 09 016 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biosignatures of Chronic Drug Exposure (R21) Apply for RFA DA 09 022 Funding Number: RFA DA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Epidemiology and Services Research in Cooperation with the Clinical and Translational Science Awards Consortium (R01) Apply for PAS 09 001 Funding Number: PAS 09 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Small Grants Program for Cancer Epidemiology (R03) Apply for PAR 08 237 Funding Number: PAR 08 237 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Unique Interactions Between Tobacco Use and HIV/AIDS (R01) Apply for PA 08 253 Funding Number: PA 08 253 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Unique Interactions Between Tobacco Use and HIV/AIDS (R03) Apply for PA 08 254 Funding Number: PA 08 254 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R01) Apply for PA 08 263 Funding Number: PA 08 263 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Small Grants for Behavioral Research in Cancer Control (R03) Apply for PAR 09 003 Funding Number: PAR 09 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery(R01) Apply for PA 09 004 Funding Number: PA 09 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21) Apply for PA 09 005 Funding Number: PA 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R21) Apply for PA 08 264 Funding Number: PA 08 264 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R03) Apply for PA 08 265 Funding Number: PA 08 265 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21) Apply for PA 08 267 Funding Number: PA 08 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 15 331", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.